CD274 and non-small cell lung carcinoma: Given the intrinsic limitations of tissue biomarkers, such as PD-L1 TPS, especially for the purpose of longitudinal real-time monitoring of patients with advanced NSCLC, there is an ongoing quest for the identification of blood-based predictors, enabling repeat evaluations throughout the disease and treatment course, without the need for invasive sampling methods.